Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.58 |
| ▸ | EGFR | P00533 | 13/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | CSK | P41240 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484041 | 0.92 | EGFR (0.68) | ERBB2EGFRERBB3ERBB4BMPR1B | |
| SCHEMBL3484211 | 0.92 | EGFR (0.66) | ERBB2EGFRERBB3ERBB4BMPR1B | |
| SCHEMBL2747416 | 0.85 | ERBB2 (0.59) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL3484827 | 0.85 | EGFR (0.77) | ERBB2EGFRERBB3ERBB4BMPR1B | |
| SCHEMBL13226099 | 0.80 | ERBB2 (0.84) | ERBB2EGFRERBB3ERBB4BMPR1B | |
| Hydrochloric Acid SCHEMBL3509595 | 0.79 | ERBB2 (0.83) | ERBB2EGFRERBB3ERBB4BMPR1B | |
| SCHEMBL2748239 | 0.79 | ERBB2 (0.62) | ERBB2EGFRERBB3ERBB4MAP2K5 | |
| SCHEMBL2747716 | 0.79 | ERBB2 (0.58) | ERBB2EGFRERBB3ERBB4BMPR1B | |
| SCHEMBL2748913 | 0.78 | EGFR (0.67) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL13541951 | 0.77 | ERBB2 (0.42) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | ERBB2 1/4885EGFR 13/4885ERBB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.